Roth Capital Reiterates Buy Rating on Aimmune Therapeutics (AIMT)
Tweet Send to a Friend
Roth Capital analyst Zegneh Jallah reiterated a Buy rating and $45.00 price target on Aimmune Therapeutics (NASDAQ: AIMT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
